iBio (IBIO)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	11.26 mm	11.26 mm	11.26 mm	11.26 mm	11.26 mm	11.26 mm
Cash burn (monthly)	1.05 mm	(no burn)	1.37 mm	1.30 mm	1.24 mm	1.41 mm
Cash used (since last report)	2.96 mm	n/a	3.84 mm	3.66 mm	3.47 mm	3.96 mm
Cash remaining	8.30 mm	n/a	7.42 mm	7.60 mm	7.79 mm	7.30 mm
Runway (months of cash)	7.9	n/a	5.4	5.8	6.3	5.2

Beta Read what these cash burn values mean

Financial data from iBio earnings reports.

Institutional ownership, Q2 2024

IBIO institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	13	29	-55.2%
Opened positions	2	29	-93.1%
Closed positions	18	0	NEW
Increased positions	0	0
Reduced positions	5	0	NEW

13F shares	Current	Prev Q	Change
Total value	2.57 bn	8.94 bn	-71.3%
Total shares	2.01 mm	3.95 mm	-49.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
ADAR1 Partners	789.29 k	$908.00 k	0.0%
Ikarian Capital	600.00 k	$1.27 bn	0.0%
Opaleye Management	375.00 k	$791.25 mm	-44.9%
Lynx1 Capital Management	240.76 k	$508.01 mm	-72.6%
IFP Advisors	1.00 k	$2.11 mm	0.0%
Group One Trading	156.00	$329.00 k	-3.1%
BAC Bank of America	71.00	$150.00 k	NEW
MS Morgan Stanley	49.00	$103.00 k	-81.7%
Harbour Investments	40.00	$84.00 k	0.0%
RY Royal Bank of Canada	37.00	$0.00	-28.8%

Largest transactions	Shares	Bought/sold	Change
Lynx1 Capital Management	240.76 k	-637.73 k	-72.6%
ADAR1 Capital Management	0.00	-600.00 k	EXIT
Armistice Capital	0.00	-350.88 k	EXIT
Opaleye Management	375.00 k	-305.00 k	-44.9%
Renaissance Technologies	0.00	-15.88 k	EXIT
Sabby Management	0.00	-14.00 k	EXIT
FNY Investment Advisers	0.00	-9.00 k	EXIT
BLK BlackRock	0.00	-5.82 k	EXIT
Tower Research Capital	0.00	-5.60 k	EXIT
UBS UBS	0.00	-1.88 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IBIO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Nov 24	Clark William D	Stock Option Common Stock	Grant	Acquire A	No	No	2.45	18,900	46.31 k	18,900
21 Nov 24	David Arkowitz	Stock Option Common Stock	Grant	Acquire A	No	No	2.45	12,600	30.87 k	12,600
21 Nov 24	Evert B. Schimmelpennink	Stock Option Common Stock	Grant	Acquire A	No	No	2.45	18,900	46.31 k	18,900
21 Nov 24	Alexandra Kropotova	Stock Option Common Stock	Grant	Acquire A	No	No	2.45	18,900	46.31 k	18,900
21 Nov 24	Gary Sender	Stock Option Common Stock	Grant	Acquire A	No	No	2.45	18,900	46.31 k	18,900

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

LUCID CAPITAL MARKETS Initiates Coverage On iBio with Buy Rating, Announces Price Target of $6

17 Dec 24

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on iBio (AMEX:IBIO) with a Buy rating and announces Price Target of $6.

iBio Q1 EPS $(0.46) Beats $(0.48) Estimate

12 Nov 24

iBio (AMEX:IBIO) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.48) by 4.17 percent. This is a 89.15 percent increase over losses of $(4.24) per share from the same period

12 Health Care Stocks Moving In Monday's Intraday Session

7 Oct 24

12 Health Care Stocks Moving In Monday's Pre-Market Session

7 Oct 24